Jiyin Zhou

This paper proposes that by means of policy guidance and technical support provided by regulatory authorities, risk assessment and hierarchical management conducted by clinical research management departments, the development of investigator-initiated trials using unlisted medical devices in China can be promoted towards a more scientific and standardized direction.